Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
MAZE 
Maze Therapeutics, Inc. Common Stock (MAZE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: MAZE (3-star) is a STRONG-BUY. BUY since 67 days. Simulated Profits (142.57%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $43.25
1 Year Target Price $43.25
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 112.95% | Avg. Invested days 35 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.87B USD | Price to earnings Ratio - | 1Y Target Price 43.25 |
Price to earnings Ratio - | 1Y Target Price 43.25 | ||
Volume (30-day avg) 4 | Beta - | 52 Weeks Range 6.71 - 43.29 | Updated Date 12/13/2025 |
52 Weeks Range 6.71 - 43.29 | Updated Date 12/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.56 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.37% | Return on Equity (TTM) -52.69% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1510169593 | Price to Sales(TTM) 3.14 |
Enterprise Value 1510169593 | Price to Sales(TTM) 3.14 | ||
Enterprise Value to Revenue 369.01 | Enterprise Value to EBITDA 6.71 | Shares Outstanding 48119444 | Shares Floating 27046977 |
Shares Outstanding 48119444 | Shares Floating 27046977 | ||
Percent Insiders 1.88 | Percent Institutions 86.2 |
About Maze Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2025-01-31 | CEO & Director Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 125 | Website https://www.mazetx.com |
Full time employees 125 | Website https://www.mazetx.com | ||
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.